Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance

Neurology

Volumn 47, Issue 5, 1996, Pages 1227-1233

  Notermans, N C ^a,b   Lokhorst, H M ^a   Franssen, H ^a   Van Der Graaf, Y ^a   Teunissen, L L ^a   Jennekens, F G I ^a   Van Den Berg, L H ^a   Wokke, J H J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; PREDNISONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMYELINATING DISEASE; DISABILITY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HUMAN; LEUKOPENIA; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; NEUROLOGIC EXAMINATION; ORAL DRUG ADMINISTRATION; POLYNEUROPATHY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0029854683     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.5.1227     Document Type: Article

References (45)

1. Notermans NC, Wokke JHJ, Lokhorst H, Franssen H, van der Graaf Y, Jennekens FGI. A prospective study of polyneuropathy associated with benign gammopathy. Clinical features, laboratory parameters and their prognostic value. Brain 1994; 117:1385-1393.
2. Gosselin S, Kyle R, Dyck P. Neuropathy associated with monoclonal gammopathies of undetermined significance. Ann Neurol 1991;30:54-61.
3. Smith IS. The natural history of chronic demyelinating neuropathy associated with benign IgM paraproteinaemia. A clinical and neurophysiological study. Brain 1994;117:949-957.
4. Suarez GA, Kelly JJ. Polyneuropathy associated with monoclonal gammopathy of undetermined significance: further evidence that IgM-MGUS neuropathies are different than IgG-MGUS. Neurology 1993;43:1304-1308.
5. Yeung KB, Thomas PK, King RHM, et al. The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. J Neurol 1991; 238:383-391.
6. Mendell JR, Sahenk Z, Whitaker JN, et al. Polyneuropathy and IgM monoclonal gammopathy: studies on the pathogenetic role of anti-myelin-associated glycoprotein antibody. Ann Neurol 1985;17:243-254.
7. Melmed C, Frail D, Duncan I, et al. Peripheral neuropathy with IgM kappa monoclonal immunoglobulin directed against myelin-associated glycoprotein. Neurology 1983;33:1397-1405.
8. Nobile-Orazio E, Manfredini E, Carpo M, et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol 1994;36:416-424.
9. Abrams GM, Latov N, Hays AP, et al. Immunocytochemical studies of human peripheral nerve with serum from patients with polyneuropathy and paraproteinemia. Neurology 1982; 32:821-826.
10. Takatsu M, Hays AP, Latov N, et al. Immunofluorescence study of patients with neuropathy and IgM-M proteins. Ann Neurol 1985;18:173-181.
11. Tatum AH. Experimental paraprotein neuropathy, demyelination by passive transfer of human IgM anti-myelin-associated-glycoprotein. Ann Neurol 1993;33:502-506.
12. Dalakas MC, Engel W. Polyneuropathy with monoclonal gammopathy: studies of 11 patients. Ann Neurol 1981;10:45-52.
13. Meier C, Roberts K, Steck A, et al. Polyneuropathy in Waldenström's macroglobulinaemia: reduction of endoneurial IgM-deposits after treatment with chlorambucil and plasmapheresis. Acta Neuropathol (Berl) 1984;64:297-307.
14. Sherman WH, Olarte MR, McKiernan G, et al. Plasma exchange treatment of peripheral neuropathy associated with plasma cell dyscrasia. J Neurol Neurosurg Psychiatry 1984; 47:813-819.
15. Ernerudh J, Brodtkorb E, Olsson T, et al. Peripheral neuropathy and monoclonal IgM with antibody activity against peripheral nerve myelin: effect of plasma exchange. J Neuroimmunol 1986;11:171-178.
16. Kelly JJ, Adelman LS, Berkamn E. Polyneuropathies associated with IgM monoclonal gammopathies. Arch Neurol 1988; 45:1355-1359.
17. Haas DC, Tatum AH. Plasmapheresis alleviates neuropathy accompanying IgM anti-MAG paraproteinemia. Ann Neurol 1988;24:83-97.
18. Nobile-Orazio E, Baldini L, Barbieri S, et al. Treatment of patients with neuropathy and anti-MAG IgM M-proteins. Ann Neurol 1988;24:83-97.
19. Cook D, Dalakas M, Galdi A, et al. High dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology 1990; 40:212-214.
20. Fineman SM, McKendall RR, Plasma exchange: a treatment for neuropathy associated with IgG-kappa gammopathy. J Neurol 1990;237:85-87.
21. Dyck PJ, Low PA, Windebank AJ, et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 1991;325:1482-1486.
22. Waterston JA, Brown MM, Ingram DA, Swash M. Cyclosporin, a therapy in paraprotein-associated neuropathy. Muscle Nerve 1992;15:445-448.
23. Blume G, Pestronk A, Goodnough LT. Anti-MAG antibody-associated polyneuropathies: improvement following immunotherapy with monthly plasma exchange and TV cyclophosphamide. Neurology 1995;45:1577-1580.
24. Oksenhendler E, Chrevet S, Leger JM, et al. Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. J Neurol Neursurg Psychiatry 1995;59: 243-247.
25. Latov NL. Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Ann Neurol 1995; 37(S1):S32-S42.
26. Roeser HP, Hocker GK, Kynaston B, et al. Advanced nonHodgkin's lymphomas: response to treatment with combination chemotherapy and factors influencing prognosis. Br J Haematol 1975;30:323-327.
27. Notermans NC, Wokke JHJ, Jennekens FGI. Clinical work-up of the patient with a polyneuropathy. In: De Jong JMBV, ed. Handbook of neurology. Amsterdam: Elsevier Science Publishers, 1991:253-270.
28. Notermans NC, van Dijk GW, van der Graaf Y, van Gijn J, Wokke JHJ. Measuring ataxia: quantification based on the standard neurological examination. J Neurol Neurosurg Psychiatry 1994;57:22-26.
29. Halonen P. Quantitative vibration perception thresholds in healthy subjects of working age. Eur J Appl Physiol 1986;54: 647-655.
30. Van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for assessment of handicap in stroke patients. Stroke 1988;19:209-212.
31. Notermans NC, Franssen H, Wieneke G, Wokke JHJ. Temperature dependence of nerve conduction and EMG in neuropathy associated with gammopathy. Muscle Nerve 1994;17: 516-522.
32. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994; 36:838-845.
33. Shahani BT, Young RR, Potts F, Maccabee P. Terminal latency index (TLI) and late response studies in motor neuron disease (MND), peripheral neuropathies and entrapment syndromes. Acta Neurol Scand 1979;Suppl 73:118.
34. Kaku DA, England JD, Summner AJ. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Brain 1994;117:941-947.
35. Ad hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy CIDP. Neurology 1991;41: 617-618.
36. Lange DJ, Trojaborg W, Latov N, et al. Multifocal motor neuropathy with conduction block: is it a distinct entity? Neurology 1992;42:497-505.
37. Van den Berg LH, Sadiq SA, Thomas FP, Latov N. Characterization of HNK-1 bearing glycoprotein in human peripheral nerve myelin. J Neurosci Res 1990;25:295-299.
38. Van den Berg LH, Marrink J, De Jager AEJ, et al. Anti-GM1 antibodies in patients with Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1992;52:8-11.
39. Van den Berg LH, Langkamp CLAM, De Jager AEJ, et al. Anti-sulphatide antibodies in peripheral neuropathy. J Neurol Neurosurg Psychiatry 1993;56:1164-1168.
40. Nemni R, Fazio R, Quattrine A, et al. Antibodies to sulphatide and to chondroitin C in patients with chronic sensory neuropathy. J Neuroimmunol 1993;43:79-86.
41. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-211.
42. Axelsson U, Bachmann R, Hallen J. Frequency of pathological proteins (M-components) in 6,995 sera from an adult population. Acta Med Scand 1966;179:235-247.
43. Kyle RA, Finkelstein S, Elveback LR, Kurland LT. Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma. Blood 1972;40:719-724.
44. Nobile-Orazio E, Marmiroli P, Baldini L, et al. Peripheral neuropathy in macroglobulinemia: incidence and antigenspecificity of M-proteins. Neurology 1987;37:1506-1514.
45. Kyle RA. Second malignancies associated with chemotherapy. In: Perry MC, Yarbro JW, eds. Toxicity of chemotherapy. New York: Grune & Stratton, 1984;479-506.